Incremental cost-effectiveness and tolerability of Diclofenac + Proton pump inhibitor compared to tramadol in the treatment of knee osteoarthritis
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20180094Keywords:
Cost-effectiveness, Diclofenac, KOOS, Osteoarthritis, Protein pump inhibitor, Tramadol, VASAbstract
Background: In a climate of economic uncertainty, cost effectiveness analysis is a potentially important tool for making choices about health care interventions. Patients with knee osteoarthritis are treated mostly with Diclofenac (NSAID) + Proton Pump Inhibitors (PPI) and Tramadol (Opioids) in everyday practice.
Aim: Present study was aimed to assess clinical effectiveness, adverse events and cost-effectiveness between Diclofenac + PPI and Tramadol.
Methods: Authors conducted prospective randomised control open label study on 40 patients at Orthopedic OPD of tertiary care hospital. Patients were given either Tramadol controlled releases tablets (200mg CR OD) or Diclofenac sustained release tablets (100mg SR OD) + PPI (Omeprazole 20mg OD) for two weeks. Clinical effectiveness was assessed by KOOS osteoarthritis index score consisting of five parameters and visual analogue scale. Suspected ADRs were recorded and incremental cost effective ratio for both drugs was calculated.
Results: After application of KOOS questionnaire Authors found net quality gain in symptoms was 24.45 in diclofenac +PPI group which was much higher against 14.15 found in tramadol group. Again ADR profile of tramadol was 29 with nausea and somnolence topping the list which was far more than only 10 in DIC +PPI group. Lastly cost-effective analysis was done where again DIC+PPI showed average cost effective ratio 5.73 verses tramadol 11.8 with an incremental cost-effectiveness ratio (ICER) of -2.72.
Conclusions: Diclofenac +PPI is as effective as tramadol in the treatment of pain due to knee osteoarthritis with the potential for feAuthorsr side effects. Diclofenac + PPI was also found to be cost-effective when compared with tramado.References
Zhang W, Doherty M, Peat G, Bierma-Zeinstra MA, Arden NK, Bresnihan B, et al. EULAR evidence-based recommendations for the diagnosis of knee osteoarthritis. Ann Rheum Dis. 2010 Mar;69(3):483-9.
Ajit N, Nandish B, Fernandes R, Roga1 G, Kasthuri A, Shanbhag D, et al. Prevalence of knee osteoarthritis in rural areas of Bangalore urban district. IJRCI. 2014;1:1-3.
Chopra A, Patil J, Billempelly V, Relwani J, Tandle HS. Prevalence of rheumatic diseases in a rural population in western India: a WHO-ILAR COPCORD Study. J Assoc Physicians India. 2001 Feb;49:240-6.
Barron MC, Rubin BR. Managing osteoarthritic knee pain. J Am Osteopath Assoc. 2007;10710(6):ES21-27.
Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoar Thr Cartil. 2008;16:137-62.
Hooper L, Brown TJ, Elliott R, Payne K, Roberts C, Symmons D. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review. BMJ. 2004;329:948.
Detsky AS, Nsglie IG. A clinician’s guide to cost effectiveness Analysis. Ann. Intern. Med. 1990;113:147-54.
Jensen MP, Chen C, Brugger AM. Interpretation of visual analog scale ratings and change scores: a reanalysis of two clinical trials of post-operative pain. J Pain. 2003;4:407-14.
Joyce CR, Zutshi DW, Hrubes VF, Mason RM. Comparison of fixed interval and visual analogue scales for rating chronic pain. Eur J Clin Pharmacol. 1975;8:415-20.
Roos EM, Toksvig-Larsen S. Knee injury and Osteoarthritis Outcome Score (KOOS) - validation and comparison to the WOMAC in total knee replacement. Health Qual Life Outcomes. 2003;1:17-8.
Azimi NA, Welch HG. The effectiveness of cost-effectiveness analysis in containing costs. J. Gen Intern Med. 1998;13:664-9.
Bang H. Median-Based Incremental Cost-Effectiveness Ratio (ICER). Stat Theory Pract. 2012;6(3):428-42.
Bodalia B, McDonald CJ, Smith KJ, O’Brien C, Cousens L. A comparison of the pharmacokinetics, clinical efficacy, and tolerability of once-daily tramadol tablets with normal release tramadol capsules. J Pain Symptom Manage. 2003;25:142-9.
Adler L, McDonald C, O’Brien C, Wilson M. A comparison of once-daily tramadol with normal release tramadol in the treatment of pain in osteoarthritis. J Rheumatol. 2002;29:219-69.
Salve H, Gupta V, Palanivel C, Yadav K, Singh B. Prevalence of knee Osteoarthritis amongst perimenopausal women in an urban resettlement colony in South Delhi. Indian J Public Health. 2010;54:155-7.
Beaulieu AD, Peloso P, Bensen W. A randomized, double-blind, 8-week crossover study of once-daily controlled-release tramadol versus immediate-release tramadol taken as needed for chronic noncancer pain. Clin Ther. 2007;29:49-60.
Pavelka K, Peliskova Z, Stehlikova H, Ratcliffe S, Repas C. Intra individual differences in pain relief and functional improvement in osteoarthritis with diclofenac or tramadol. Clin Drug Investig. 1998;16:421-9.
Fowler PD, Shadforth MF, Crook PR, John VA. Plasma and synovial fluid concentrations of diclofenac sodium and its major hydroxylated metabolites during long-term treatment of rheumatoid arthritis. Eur. J. Clin. Pharmacol. 1983;25(3):389-94.
Suzuki M, Nakamura M, Mori M, Miura S, Tsuchiya M, Ishil H. Lansoprazole inhibits oxygen-derived free radical production from neutrophils activated by Helicobacter pylori. J Clin Gastroenterol. 1995;20(2):S93-S96.
Ohara T, Arakawa T. Lansoprazole decreases peripheral blood monocytes and intercellular adhesion molecule-1-positive mononuclear cells. Dig Dis Sci. 1999;44:1710-15.
Becker JC, Grosser N, Waltke C. Beyond gastric acid reduction: proton pumpinhibitors induce heme oxygenase-1 in gastric and endothelial cells. Biochem Biophys Res Commun. 2006;345:1014-21.
Jamtvedt G, Dahm KT, Christie A. Physical therapy interventions for patients with osteoarthritis of the knee: an overview of systematic reviews. Phys Ther. 2008;88(1):123-36.
Dalgin P. For the TPS-OA study group Comparison of tramadol and ibuprofen for the chronic pain of osteoarthritis Arthritis Rheum. 1997;40(9):S86.
Simon L, Lipman A, Jacox A. Guideline for the Management of Pain in Osteoarthritis Rheumatoid Arthritis and Juvenile Chronic Arthritis. 2nd Ed. Glenview: American Pain Society; 2002.
Sorge J, Stadler TH. Comparison of the analgesic efficacy and tolerability of tramadol 100 mg sustained-release tablets and tramadol 50 mg capsules for the treatment of chronic low back pain. Clin Drug Investig. 1997;14:157-64.
Ofman JJ, MacLean CH, Straus WL. A meta-analysis of severe upper gastrointestinal complications of nonsteroidal anti-inflammatory drugs. J Rheumatol. 2002;29:804-12.
Emkey R, Rosenthal N, Wu SC, Jordan D, Kamin M. CAPSS-114 Study Group. Efficacy and safety of tramadol/acetaminophen tablets (Ultra cet) as add-on therapy for osteoarthritis pain in subjects receiving a COX-2 non-steroidal anti inflammatory drug: A multicenter, randomized, double-blind, placebo-controlled trial. J Rheumatol. 2004;31:150-6.
Liedgens H, Nuijten MJ, Nautrup BP. Economic evaluation of tramadol/ paracetamol combination tablets for osteoarthritis pain in the Netherlands. Clin Drug Investig. 2005;25:785-802.
Bang H. Median-Based Incremental Cost-Effectiveness Ratio (ICER). Stat Theory Pract. 2012;6(3):428-42.
